Epigenetic Technologies Market Dynamics 2021-2031
[Research Report] The epigenetic technologies market size was valued at US$ 7,697.56 million in 2022 and is expected to reach US$ 22, 922.65 million by 2031; it is estimated to register a CAGR of 19.20% from 2022 to 2031.
Market Insights and Analyst View:
Epigenetics is the study of changes in gene expression caused by environmental factors rather than changes in the DNA sequence itself. It refers to inheritable changes in an organism's traits that occur independently of its genetic material. This involves DNA methylation and histone modifications, which can be analyzed using various techniques. These changes cause variations in an organism's phenotype instead of genotype, and they are essential for development as they respond to environmental stimuli.
Key factors driving the epigenetic technologies market growth include the surge in the use of epigenetics technologies for drug development and increasing funding, investment, and approvals for research and development in the field of epigenetics. However, standardization regarding epigenetics-based diagnostics and a scarcity of experienced practitioners is projected to impede market expansion.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Epigenetic Technologies Market: Strategic Insights
Market Size Value in US$ 7,697.56 million in 2022 Market Size Value by US$ 22, 922.65 million by 2030 Growth rate CAGR of 19.20% from 2022 to 2030 Forecast Period 2022-2030 Base Year 2022
Naveen
Have a question?
Naveen will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Epigenetic Technologies Market: Strategic Insights
| Market Size Value in | US$ 7,697.56 million in 2022 |
| Market Size Value by | US$ 22, 922.65 million by 2030 |
| Growth rate | CAGR of 19.20% from 2022 to 2030 |
| Forecast Period | 2022-2030 |
| Base Year | 2022 |
Naveen
Have a question?
Naveen will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Growth Drivers and Restraints:
The field of epigenetic drug discovery offers numerous possibilities for detecting novel therapeutic agents. Epigenetic drug development targets noncoding RNA expression, DNA methylation, and histone modifications. Epigenetic mechanisms are important for gene transcription, maintaining genomic stability, and enabling normal cell growth, development, and differentiation. However, epigenetic dysregulation can lead to the onset and progression of various human diseases, such as cancer, cardiovascular diseases, metabolic diseases, and neurological diseases. According to the World Health Organization (WHO), cancer caused almost 10 million deaths in 2021, representing one in six deaths. The most common cancers include breast, lung, colon, rectum, and prostate cancers. Epigenetics is a field with promising tools that can serve various purposes such as prevention, diagnosis, and treatment; by developing drugs that target specific epigenetic mechanisms responsible for regulating gene expression, it is possible to effectively apply epigenetic tools to treat various diseases, including cancer. According to the article published by the American Cancer Society in December 2022, epigenetic modifications, specifically shifts in DNA methylation and histone mark patterns, play a crucial role in tumor progression and metastasis. These cancer-specific events have proven useful tools for diagnosing, monitoring, and determining treatment options to assist with clinical decision-making. Additionally, the epigenetic machinery's ability to reverse modifications, in contrast to genetic changes' irreversibility, has made it an attractive target for drug development.
Moreover, adopting high-throughput technologies, including next-generation sequencing (NGS) and mass spectrometry (MS) into clinical laboratories, as well as the development of epigenetic biomarkers, will aid in the introduction of new epigenetics-based in vitro diagnostic (IVD) tests, thereby expanding its clinical applications. According to an article published by ScienceDirect in 2021, two complementing PCR-based strategies such as methylation-sensitive and methylation-specific techniques. Enrichment assays have also been developed to identify low-abundance methylation or unmethylated DNA, which can be employed in noninvasive blood testing.
Therefore, the increase in cases of cancer and genetic disorders has, in turn, led to the rise in research and development of various epigenetic technologies for drug discovery and development to treat these diseases.
Furthermore, the growing use of epigenetics in non-oncology applications such as drug development for infectious diseases and autoimmune diseases and the growing patient pool for customized treatment provide profitable potential for the industry; hence, there is a big epigenetics market opportunity for major firms to invest in.
However, standardization concerns regarding epigenetics-based diagnostics and a scarcity of experienced practitioners are projected to impede market expansion.
Market Scope and Segmentation
The global epigenetics technologies market is segmented based on type, components, applications, technique, end users, and geography. The epigenetics technologies market is segmented based on type into NGS, PCR and QPCR, Mass spectrometry, Sonication, and others. The epigenetics technologies market is bifurcated based on components into products and services. Based on application, the market is segmented into oncology, metabolic diseases, immunology, cardiovascular disorders, and others. Based on techniques, the market is segmented into DNA methylation, histone modification, and regulation by noncoding RNAs. Based on end users, the market is segmented into Contract Research Organizations, academic and research institutions, and pharmaceutical and biotech industries. The epigenetics technologies market, based on geography, is segmented into North America (the US, Canada, and Mexico), Europe (Germany, France, Italy, the UK, Russia, and the Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).
Segmental Analysis:
The epigenetics technologies market, by type, is segmented into NGS, PCR and QPCR, Mass spectrometry, Sonication, and others. The NGS held the largest market share in 2022 and is anticipated to register the highest CAGR in the market from 2022 to 2031. Next-generation sequencing (NGS) is a powerful sequencing technology for high throughput, scalability, and speed. This technology is utilized for determining the order of nucleotides across entire genomes or specific regions of DNA or RNA. NGS has completely transformed the biological sciences, enabling researchers to perform a broad range of applications and study biological systems at an unprecedented level.
The epigenetics technologies market is bifurcated based on components into products and services. The product segment is further sub-segmented into enzymes, instruments, kits, and reagents. Similarly, the services segment is further categorized into ChIP-Seq, CUT&Tag, DNA methylation sequencing, ATAC-Seq, gene expression, chromatin structure mapping, IP-mass spec, and single-cell services. The services segment held the largest market share in 2022, and the product segment is expected to register the highest CAGR in the market during 2022-2031.
Based on application, the market is segmented into oncology, metabolic diseases, immunology, cardiovascular disorders, etc. The oncology segment held the largest epigenetics technologies market in 2022. However, the cardiovascular segment is expected to register the highest CAGR in the market during 2022-2031. According to WHO, Cardiovascular diseases (CVDs) cause 17.9 million deaths annually owing to poor lifestyle choices such as unhealthy diet, lack of exercise, smoking, and excessive alcohol consumption. According to an article published by the European Journal of Preventive Cardiology in August 2022, CVDs are often influenced by inherited genetic variations. Certain risk factors, such as dyslipidemia, hypertension, diabetes, and obesity, are also linked to genetic traits. Researchers have identified hundreds of single-nucleotide polymorphisms (SNPs) associated with coronary artery disease. Still, these SNPs can only explain a small portion of CVD's heritability, suggesting that gene-gene interaction and/or epigenetic mechanisms contribute more than genetic variation. Experimental evidence supports a strong connection between epigenetic changes and the risk of CVD.
Based on techniques, the market is segmented into DNA methylation, histone modification, and regulation by noncoding RNAs. DNA methylation segments will hold the highest market share from 2022 to 2031.
Based on end users, the market is segmented into hospitals and clinics, academic and research institutions, and pharmaceutical and biotech industries. Academic and research institutions will hold a significant market share in 2022 owing to a rise in research studies and government investments in biotechnology. However, the pharmaceutical and biotech industries segment is expected to register the highest CAGR in the market during 2022-2031.
Regional Analysis:
Based on geography, the global epigenetic technologies market is segmented into five key regions: North America, Europe, Asia Pacific, South and Central America, and Middle East and Africa. North America is estimated to hold a larger market share during 2022–2031, owing to rising cancer prevalence and healthcare costs. The North American epigenetic technologies market is segmented into the US, Canada, and Mexico. The market growth is attributed to the increasing number of clinical trials due to ongoing drug development studies, availability of advanced epigenetics products, and various factors such as a technologically advanced healthcare system. The US has emerged as a leading clinical research destination.
Industry Developments and Future Opportunities:
Various initiatives taken by key players operating in the global epigenetic technologies market are listed below:
- In November 2023, QIAGEN launched the Microbiome WGS SeqSets, a comprehensive and user-friendly workflow for efficient and reproducible microbiome research. The workflow simplifies sample extraction and next-generation sequencing (NGS) library preparation and user-friendly bioinformatics analysis for non-experts making analysis more accessible.
- In November 2023, EpiCypher launched a fully automated CUT&RUN assay called autoCUT&RUN, allowing for high-throughput chromatin feature mapping. This technology is a significant breakthrough in epigenomic profiling, as it is based on EpiCypher's industry-leading CUTANA CUT&RUN kits. The autoCUT&RUN assay enables scaled research, advancing therapeutic development and biomarker discovery.
- In April 2023, Cambridge Epigenetix, rebranded as Biomodal, introduced their new duet multiomics solution, combining genetic and epigenetic data from a single low-volume sample. The duet multiomics solution is the first single-base-resolution sequencing technique that allows for the simultaneous phased reading of genomic and epigenetic information in a single sample using current sequencing equipment and a single procedure.
- In September 2021, Active Motif collaborated with Proteintech Group. Active Motif received an investment from Proteintech Group, an original manufacturer of antibodies, nanobodies, and recombinant proteins. Active Motif has announced that it plans to use the funds to augment its R&D capabilities and expand its commercial reach. With Proteintech as a strategic partner, the company stands to gain a cash boost, access to high-quality antibodies, and an expanded distribution network.
- In April 2022, PacBio, a leading producer of high-quality, highly accurate sequencing systems, game-changing Sequel IIe and Sequel II Systems, and detection capabilities for DNA methylation. PacBio's unique and highly efficient HiFi sequencing method includes access to the epigenome, a second layer of genomic information frequently overlooked due to inherent limitations of standard sequencing technologies.
Competitive Landscape and Key Companies:
Illumina Inc., BioRad Laboratories, QIAGEN N.V., Thermo Fisher Scientific Inc., Abcam Plc, PerkinElmer, Inc., Agilent Technologies Inc., Zymo Research Corporation, Merck Millipore, Active Motif, Inc. are among the prominent players operating in the epigenetic technologies market. These companies focus on new technologies, advancements in existing products, and geographic expansions to meet the growing consumer demand worldwide and increase their product range in specialty portfolios.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Type, Components, Application, Techniques, End Users, and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
- Illumina Inc.
- BioRad Laboratories
- QIAGEN N.V.
- Thermo Fisher Scientific Inc.
- Abcam Plc
- PerkinElmer, Inc.
- Agilent Technologies Inc.
- Zymo Research Corporation
- Merck Millipore
- Active Motif, Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For